Cash Flow ERIS Lifescience Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Profit Before Tax
488.00
431.00
404.00
442.00
394.00
331.00
Adjustment
548.00
254.00
139.00
49.00
44.00
44.00
Changes In working Capital
125.00
-98.00
-175.00
-29.00
5.00
-52.00
Cash Flow after changes in Working Capital
1,162.00
586.00
368.00
461.00
443.00
322.00
Cash Flow from Operating Activities
1,065.00
486.00
291.00
378.00
375.00
271.00
Cash Flow from Investing Activities
-78.00
-1,827.00
-974.00
-319.00
-323.00
123.00
Cash Flow from Financing Activities
-881.00
1,379.00
688.00
-44.00
-82.00
-334.00
Net Cash Inflow / Outflow
105.00
38.00
5.00
13.00
-30.00
59.00
Opening Cash & Cash Equivalents
94.00
56.00
50.00
36.00
67.00
7.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
199.00
94.00
56.00
50.00
36.00
67.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of ERIS Lifescience
Figures in Cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
488.87
-16
504.00
3155.44%
Adjustment
548.05
455
93.00
20.45%
Changes In working Capital
125.97
-492
617.00
125.60%
Cash Flow after changes in Working Capital
1162.89
-53
1,215.00
2294.13%
Cash Flow from Operating Activities
1065.01
-22
1,087.00
4940.95%
Cash Flow from Investing Activities
-78.2
-780
702.00
89.97%
Cash Flow from Financing Activities
-881.32
409
-1,290.00
-315.48%
Net Cash Inflow / Outflow
105.49
-393
498.00
126.84%
Opening Cash & Cash Equivalents
94.25
505
-411.00
-81.34%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
199.74
112
87.00
78.34%
Cash Flow - Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 119.13% vs 66.59% in Mar 2024
Mar'25
Mar'24
Change(%)
Cash Flow from Operating Activities
1,065.01
486.01
119.13%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
